Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Jorge E. Cortes 1*, Florian H. Heidel 2,3, Walter Fiedler 4, B. Douglas Smith 5, Tadeusz Robak 6, Pau Montesinos 7, Anna Candoni 8, Brian Leber 9, Mikkael A. Sekeres 10, Daniel A. Pollyea 11, Roxanne Ferdinand 12, Weidong Wendy Ma 12, Thomas O’Brien 12, Ashleigh O’Connell 12, Geoffrey Chan 12 and Michael Heuser 13

Abstract

Background: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm (P = 0.015).

Methods: This post hoc analysis determines whether the clinical benefits of glasdegib are restricted to patients who achieve CR, or if they extend to those who do not achieve CR.

Results: In patients who did not achieve CR, the addition of glasdegib to LDAC improved overall survival (OS) versus LDAC alone (hazard ratio = 0.63 (95% confidence interval, 0.41–0.98); P = 0.0182; median OS, 5.0 vs 4.1 months). Additionally, more patients receiving glasdegib + LDAC achieved durable recovery of absolute neutrophil count (≥ 1000/μl, 45.6% vs 35.5%), hemoglobin (≥ 9 g/dl, 54.4% vs 38.7%), and platelets (≥ 100,000/μl, 29.8% vs 9.7%). Transfusion independence was achieved by 15.0% and 2.9% of patients receiving glasdegib + LDAC and LDAC alone, respectively.

Conclusions: Collectively, these data suggest that there are clinical benefits with glasdegib in the absence of CR.

Trial registration: ClinicalTrials.gov NCT01546038 (March 7, 2012)

Keywords: Glasdegib, Acute myeloid leukemia, Clinical trial, Disease response, Efficacy

* Correspondence: jorge.cortes@augusta.edu
1 Georgia Cancer Center, Augusta, CA, USA
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Glasdegib, an oral, small-molecule inhibitor of the Smoothened (SMO) receptor, selectively inhibits the Hedgehog signaling pathway. In a phase 2 randomized study that included patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy (BRIGHT AML 1003), the addition of glasdegib to low-dose cytarabine (LDAC) demonstrated superior overall survival (OS) compared with LDAC alone (hazard ratio [HR] = 0.51; 80% confidence interval [CI], 0.39–0.67; P = 0.0004; median OS 8.8 vs 4.9 months). The combination of glasdegib and LDAC was generally well tolerated, with a manageable safety profile, consistent with findings in older patients receiving chemotherapy, and with “class effect” toxicities reported for other marketed SMO inhibitors. The combination did not appear to increase cytopenias, bleeding, or infection [1]. Based on the findings from BRIGHT AML 1003, glasdegib was approved in the USA, in combination with LDAC, for the treatment of newly diagnosed AML in patients unable to receive intensive chemotherapy due to comorbidities or age (≥75 years) [2].

Despite a significantly higher response rate with glasdegib + LDAC compared with LDAC alone, the majority of patients in the BRIGHT AML 1003 study did not achieve complete remission (CR) [1]. Given the importance of the Hedgehog signaling pathway in the maintenance of leukemic stem cells (LSCs), but not normal adult hematopoiesis, and the effect of glasdegib on LSCs, we hypothesized that there would be clinical benefits for patients treated with glasdegib regardless of whether they achieved a CR or not [3–6]. We thus performed this post hoc analysis to determine whether the survival and clinical benefits of glasdegib are restricted to patients who achieve CR or if it extends to those who do not achieve CR.

Methods
Study design and patients
BRIGHT AML 1003 (ClinicalTrials.gov, NCT01546038) was an open-label, randomized, multicenter, phase 2 study for which the methods have previously been published [1]. Briefly, BRIGHT AML 1003 enrolled patients aged ≥55 years with newly diagnosed, previously untreated AML or high-risk myelodysplastic syndromes (World Health Organization 2008 classification) who were ineligible for intensive chemotherapy. Ineligibility for intensive chemotherapy was defined as meeting one or more of the following criteria: age ≥75 years, serum creatinine >1.3 mg/dl, severe cardiac disease (e.g., left ventricular ejection fraction < 45% by multigated acquisition or echocardiography at screening), or Eastern Cooperative Oncology Group performance status = 2. Patients were randomized 2:1 to receive glasdegib + LDAC or LDAC alone. Glasdegib 100 mg once daily was administered orally in 28-day cycles on a continuous basis, and LDAC 20 mg was administered subcutaneously twice daily for 10 days, every 28 days, until disease progression, unacceptable toxicity, or patient refusal. This analysis assessed efficacy and safety in patients with AML only; the data cut-off date was October 2018.

The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent before study procedures began, and the protocol was approved by institutional review boards at each study site.

Efficacy and safety assessments
This post hoc exploratory analysis assessed efficacy and safety in patients with AML who achieved CR and those who did not achieve CR (including patients with CR with incomplete hematologic response [CRi]) at any point during treatment. Response to treatment was assessed based on the International Working Group response criteria for AML [7]. CR was defined as <5% bone marrow blasts, no extramedullary disease, absolute neutrophil count (ANC) ≥1000/μl, platelet count ≥100,000/μl, and transfusion independent. CRi was defined as <5% bone marrow blasts, no extramedullary disease, and with either neutrophils or platelets not recovered to CR levels. Bone marrow samples for response assessment were collected at screening; on cycle 3, day 1; and every third cycle, within 14 days of achieving initial hematologic recovery in the peripheral blood (defined as ANC >1000/μl and platelets ≥100,000/μl), at end of treatment, and at the investigator’s discretion (±7 days of nominal time).

Safety assessments included adverse events (AEs), classified and graded based on the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0, based on history and physical exam, vital signs, laboratory evaluations, and 12-lead electrocardiograms.

Statistical analysis
After discontinuation of study treatment, patients were followed until death or for 4 years from first dose. OS was defined as the time from date of randomization to death from any cause. Patients not known to have died at the last follow-up were censored on the date they were last known to be alive. OS was estimated using the Kaplan–Meier method. Transfusion independence was defined as ≥8 consecutive weeks without red blood cell and/or platelet transfusion. Safety data were summarized descriptively and included all randomized patients who received at least one dose of any of the study medications.
Results

Patients and duration of treatment

A total of 116 patients with AML were randomized to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38); among them, 75 and 36 patients received study treatments, respectively (Additional file 5: Table S1). Response rates for all patients are shown in Table 1. The response rate was significantly higher for patients who received glasdegib + LDAC compared with LDAC alone; the respective rate of CR was 19.2% versus 2.6%; P = 0.015. Patient demographics and baseline characteristics are summarized in Table 2. Of the patients who achieved CR and those who did not achieve CR, the median age at study entry was ≥ 74 years in the glasdegib + LDAC and LDAC alone arms, and more than half of patients in each subgroup were male.

Among patients who achieved CR, the median duration of treatment was 17 (range, 1–44) cycles with glasdegib + LDAC and seven cycles for the one patient receiving LDAC alone. Of the patients who did not achieve CR, the median duration of treatment was two (range, 1–43) cycles with glasdegib + LDAC and two (range, 1–9) cycles with LDAC alone; 48.3% and 37.1% of patients received ≥ 3 cycles of treatment, respectively, while 28.3% and 8.6% of patients received ≥ 6 cycles. The duration of treatment with best overall response is shown for individual patients in the Additional file 1: Fig. S1. Following ≥ 6 cycles of treatment, two patients achieved CR (cycles 6 and 32) and three patients achieved CRi (cycle 6) in the glasdegib + LDAC arm; one patient achieved CRi (cycle 6) in the LDAC alone arm. The most common reason for treatment discontinuation among all patient cohorts was insufficient clinical response.

Median follow-up for OS for all patients was 43.4 months with glasdegib + LDAC and 42.0 months with LDAC alone.

Efficacy

Patients who achieved CR

The median time to CR was 59 (range, 33–919) days with glasdegib + LDAC and 170 days for the one patient receiving LDAC alone; the median duration of CR was 302 (range, 1–1262) days and 91 days, respectively.

For patients who achieved CR, the median OS was 26.1 (95% CI, 12.3–34.6) months with glasdegib + LDAC and 12.9 months with LDAC alone (Table 3 and Fig. 1). The 12-month survival probability was 86.7% (95% CI, 56.4–96.5) for glasdegib + LDAC; the one patient with LDAC alone died at 12.9 months. The cause of death was AML in 66.7% of patients receiving glasdegib + LDAC and in the one patient receiving LDAC alone. Among patients who achieved CR, the median OS for patients receiving glasdegib + LDAC was longer in patients with secondary AML than with de novo AML (34.3 months and 14.5 months, respectively (Table 4)).

Patients who did not achieve CR

Among the patients who did not achieve CR, OS was longer with glasdegib + LDAC (n = 63) versus LDAC alone (n = 37) with HR = 0.63 (95% CI, 0.41–0.98), P = 0.0182; the median OS was 5.0 (95% CI, 3.5–8.3) months and 4.1 (95% CI, 1.9–5.3) months, respectively. The respective 12-month survival probability was 27.3% (95% CI, 16.7–39.0) and 5.7% (95% CI, 1.0–16.8). Disease progression was the cause of death in 77.8% of patients receiving glasdegib + LDAC and in 75.7% of patients receiving LDAC alone.

To try to account for the possible effect of early mortality versus treatment effect, OS was assessed in patients who did not achieve CR and received ≥ 56 days of therapy. OS was longer with glasdegib + LDAC (n = 36) versus LDAC alone (n = 13) with HR = 0.54 (95% CI, 0.27–1.05), P = 0.033, and median OS 8.3 (95% CI, 4.4–13.9) months and 5.3 (95% CI, 4.1–6.5) months, respectively. The respective 12-month survival probability was 42.9% (95% CI, 26.4–58.3) and 7.7% (95% CI, 0.5–29.2), respectively. Survival rates for patients who did not achieve either CR or CRi are shown in Additional file 2: Fig. S2.

Among patients who did not achieve CR, 27 (45.0%) in the glasdegib + LDAC arm and 10 (28.6%) in the LDAC alone arm were reported to have received follow-up systemic therapies after discontinuation of study treatment. When patients were censored at the start of follow-up systemic therapies, the median OS was 7.1 (95% CI, 3.5–14.7) months with glasdegib + LDAC and 4.1 (95% CI, 1.9–5.3) months with LDAC alone.

Table 1 Best overall response for patients with AML at any time on treatment

| Achieved CR | Glasdegib + LDAC (n = 78) | LDAC alone (n = 38) |
|-------------|--------------------------|---------------------|
| CR          | 15 (19.2)                | 1 (2.6)             |
| Did not achieve CR |                         |                     |
| CRi         | 4 (5.1)                  | 1 (2.6)             |
| PR          | 5 (6.4)                  | 0                   |
| PRi         | 2 (2.6)                  | 0                   |
| MLFS        | 2 (2.6)                  | 0                   |
| MR          | 4 (5.1)                  | 4 (10.5)            |
| SD          | 14 (17.9)                | 9 (23.7)            |
| Treatment failure | 9 (11.5)               | 7 (18.4)            |
| Not evaluable | 23 (29.5)               | 16 (42.1)           |

AML acute myeloid leukemia, CR complete remission, CRi CR with incomplete hematologic recovery, LDAC low-dose cytarabine, MLFS morphologic leukemia-free state, MR minor response, PR partial remission, PRi PR with incomplete hematologic recovery, SD stable disease
Table 2 Patient demographics and baseline characteristics

| Characteristic                     | Achieved CR | Did not achieve CR |
|-----------------------------------|-------------|--------------------|
|                                   | Glasdegib + LDAC | LDAC alone | Glasdegib + LDAC | LDAC alone |
|                                   | N = 15       | N = 1       | N = 63          | N = 37     |
| Age (years), n (%)                |              |             |
| 45–64                             | 0            | 1 (1.6)     | 1 (2.7)         |            |
| ≥ 65                              | 15 (100)     | 62 (98.4)   | 36 (97.3)       |            |
| Median (range) 74 (65–87)         | 78 (78–78)   | 77 (64–92)   | 76 (58–83)      |            |
| Sex, n (%)                        |              |             |
| Female                            | 5 (33.3)     | 14 (22.2)   | 14 (37.8)       |            |
| Male                              | 10 (66.7)    | 49 (77.8)   | 23 (62.2)       |            |
| ECOG PS, n (%)                    |              |             |
| 0                                 | 0            | 10 (15.9)   | 2 (5.4)         |            |
| 1                                 | 5 (33.3)     | 21 (33.3)   | 17 (45.9)       |            |
| 2                                 | 10 (66.7)    | 31 (49.2)   | 18 (48.6)       |            |
| Not reported                      | 0            | 1 (1.6)     | 0               |            |
| Cytogenetic risk, n (%)           |              |             |
| Good/intermediate risk            | 12 (80.0)    | 41 (65.1)   | 22 (59.5)       |            |
| Poor risk                         | 3 (20.0)     | 22 (34.9)   | 15 (40.5)       |            |
| ELN risk stratification, n (%)    |              |             |
| Favorable                         | 1 (6.7)      | 4 (6.3)     | 3 (8.1)         |            |
| Intermediate I                    | 8 (53.3)     | 19 (30.2)   | 11 (29.7)       |            |
| Intermediate II                   | 3 (20.0)     | 18 (28.6)   | 8 (21.6)        |            |
| Adverse                           | 3 (20.0)     | 22 (34.9)   | 15 (40.5)       |            |
| Disease history, n (%)            |              |             |
| De novo                           | 7 (46.7)     | 31 (49.2)   | 17 (45.9)       |            |
| Secondary AML                     | 8 (53.3)     | 32 (50.8)   | 20 (54.1)       |            |
| Mutations, n (%)*                 |              |             |
| FLT3†                             | 0            | 5 (7.9)     | 0               |            |
| IDH1 or IDH2                      | 4 (26.7)     | 15 (23.8)   | 6 (16.2)        |            |
| NPM1                              | 1 (6.7)      | 4 (6.3)     | 1 (2.7)         |            |
| Unknown                            | 4 (26.7)     | 16 (25.4)   | 13 (35.1)       |            |

AML acute myeloid leukemia, CR complete remission, ECOG PS Eastern Cooperative Oncology Group performance status, ELN European LeukemiaNet, LDAC low-dose cytarabine
*Baseline gene mutations were determined in 58/78 patients receiving glasdegib + LDAC (CR, n = 11; no CR, n = 47) and 25/38 patients receiving LDAC alone (CR, n = 1; no CR, n = 24)
†Includes only FLT3 point mutations

Table 3 OS in patients who achieved CR and those who did not achieve CR

|                  | Achieved CR | Did not achieve CR |
|------------------|-------------|--------------------|
|                  | Glasdegib + LDAC | LDAC alone | Glasdegib + LDAC | LDAC alone |
|                  | N = 15       | N = 1       | N = 63          | N = 37     |
| Median OS, months (95% CI) | 26.1 (12.3–34.6) | 12.9 (N/E–N/E) | 5.0 (3.5–8.3) | 4.1 (1.9–5.3) |
| Survival probability, % (95% CI) |             |             |                |
| 6 months         | 100 (100–100) | 100 (100–100) | 49.5 (36.3–61.5) | 31.5 (17.2–47.0) |
| 12 months        | 86.7 (56.4–96.5) | 100 (100–100) | 27.3 (16.7–39.0) | 5.7 (1.0–16.8) |
| Deaths, n (%)    | 10 (66.7)    | 1 (100)     | 49 (77.8)       | 28 (75.7)  |

CI confidence interval, CR complete remission, LDAC low-dose cytarabine, N/E not evaluable, OS overall survival
**Fig. 1** Kaplan–Meier plots of OS. 

**a** In patients who achieved CR. 
**b** In patients who did not achieve CR. Abbreviations: CI, confidence interval; CR, complete remission; HR, hazard ratio; LDAC, low-dose cytarabine; OS, overall survival

### Table 4 OS by de novo and secondary AML

|                  | De novo          | Secondary AML     |
|------------------|------------------|-------------------|
|                  | Glasdegib + LDAC| LDAC alone        | Glasdegib + LDAC | LDAC alone     |
| **Achieved CR**  |                  |                   |                  |               |
| n                | 7                | 1                 | 8                | 0              |
| Median OS, months (95% CI) | 14.5 (8.8–26.1) | 12.9 (N/E–N/E)   | 34.3 (7.4–N/E) | –              |
| Survival probability, % (95% CI) |                   |                   |                  |               |
| 6 months         | 100 (100–100)    | 100 (100–100)     | 100 (100–100)    | –              |
| 12 months        | 85.7 (33.4–97.9) | 100 (100–100)     | 87.5 (38.7–98.1) | –              |
| Deaths, n (%)    | 6 (85.7)         | 1 (100)           | 6 (75.0)         | –              |
| Cause of death: disease under study | 5 (71.4)         | 1 (100)           | 5 (62.5)         | –              |
| **Did not achieve CR** |                  |                   |                  |               |
| n                | 31               | 17                | 32               | 20             |
| Median OS, months (95% CI) | 4.4 (2.6–6.9)    | 3.9 (1.3–8.7)     | 7.5 (3.4–9.5)    | 4.1 (1.5–6.4)  |
| Survival probability, % (95% CI) |                   |                   |                  |               |
| 6 months         | 39.9 (22.1–57.1) | 31.3 (11.4–53.6)  | 58.2 (39.1–73.2) | 31.9 (13.1–52.6) |
| 12 months        | 29.0 (13.8–46.1) | 12.5 (2.1–32.8)   | 25.9 (12.2–41.9) | N/E (N/E–N/E)  |
| Deaths, n (%)    | 27 (87.1)        | 15 (88.2)         | 30 (93.8)        | 19 (95.0)      |
| Cause of death: disease under study | 23 (74.2)        | 11 (64.7)         | 26 (81.3)        | 17 (85.0)      |

AML acute myeloid leukemia, CI confidence interval, CR complete remission, LDAC low-dose cytarabine, N/E not evaluable, OS overall survival
months with glasdegib + LDAC and 3.5 (95% CI, 1.9–4.9) months with LDAC alone (HR = 0.52 [95% CI, 0.30–0.89]; P = 0.008). The respective 12-month survival probability was 39.0% (95% CI, 22.9–54.9) and 7.6% (95% CI, 0.7–26.6) (Additional file 3: Fig. S3).

Analyzing patients who did not achieve CR with regard to either de novo or secondary AML, the median OS was again longer in patients receiving glasdegib + LDAC versus LDAC alone (Table 4). Acknowledging the small numbers in this subset analysis, the improvement in OS with glasdegib + LDAC and LDAC alone, respectively. Recovery was seen as early as cycle 1 in a meaningful proportion of patients, and counts were 3, and 4). Recovery was seen as early as cycle 1 in a meaningful proportion of patients, and counts were maintained or continued to improve during subsequent cycles in the remaining patients at risk (Additional file 4: Fig. S4). In addition, among patients who did not achieve CR, transfusion independence was achieved by 9/60 patients (15.0%) receiving glasdegib + LDAC and 1/35 patients (2.9%) receiving LDAC alone (Fig. 5).

Safety
To account for imbalances in treatment duration between the glasdegib + LDAC and LDAC alone arms, AEs are presented separately for the first 90 days. All of the patients randomized and treated in both arms reported treatment-emergent AEs (TEAEs) during the course of the study. The incidence of TEAEs (any grade) was lower over the long term (after 90 days) than the short term (during the first 90 days) in patients receiving glasdegib + LDAC, regardless of whether they achieved CR or not (Table 6, Additional file 6: Table S2).

AEs thought to be linked to the inhibition of the Hedgehog signaling pathway in normal tissue appeared to occur less frequently in patients receiving glasdegib + LDAC who did not achieve CR versus those who achieved CR in the short term (alopecia, 1.7% vs 13.3%; dysgeusia, 13.3% vs 46.7%; muscle spasms, 8.3% vs 40.0%) and long term (alopecia, 6.9% vs 14.3%; dysgeusia, 6.9% vs 28.6%; muscle spasms, 10.3% vs 50.0%). However, the respective exposure-adjusted rates were similar both in the short term (alopecia, 0.0004 vs 0.0002; dysgeusia, 0.0015 vs 0.0017; muscle spasms, 0.0012 vs 0.0010) and long term (alopecia, 0.0001 vs 0.0001; dysgeusia, 0.0003 vs 0.0001; muscle spasms, 0.0005 vs 0.0002).

### Table 5 OS by cytogenetic risk

| Achieved CR | Good/intermediate | Poor |
|-------------|-------------------|------|
| Glasdegib + LDAC | n = 12 | n = 0 |
| Median OS, months (95% CI) | 30.4 (14.5–N/E) | – |
| Survival probability, % (95% CI) | |
| 6 months | 100 (100–100) | – |
| 12 months | 100 (100–100) | – |
| Deaths, n (%) | |
| Cause of death: disease under study | 7 (58.3) | – |
| Did not achieve CR | n = 41 | n = 22 |
| Glasdegib + LDAC | n = 22 |
| LDAC alone | n = 15 |
| Median OS, months (95% CI) | 7.7 (3.5–11.1) | 5.3 (3.5–8.7) |
| Survival probability, % (95% CI) | |
| 6 months | 60.7 (43.5–74.1) | 45.1 (23.2–64.8) |
| 12 months | 34.3 (19.9–49.2) | 10.0 (1.7–27.3) |
| Deaths, n (%) | |
| Cause of death: disease under study | 30 (73.2) | 15 (68.2) |

CI: confidence interval, CR: complete remission, LDAC: low-dose cytarabine, N/E: not evaluable, OS: overall survival.
Among patients who did not achieve CR, the incidence of TEAEs associated with cytopenias, bleeding, and infections generally did not appear worse with glasdegib + LDAC versus LDAC alone either in the short term (anemia, 41.7% vs 42.9%; decreased neutrophil count, 5.0% vs 2.9%; decreased platelet count, 11.7% vs 11.4%; febrile neutropenia, 28.3% vs 22.9%; hemorrhage, 11.7% vs 28.6%; neutropenia, 6.7% vs 14.3%; pneumonia, 20.0% vs 25.7%; sepsis, 5.0% vs 14.3%; thrombocytopenia, 28.3% vs 25.7%) or the long term (anemia, 27.6% vs 23.1%; decreased neutrophil count, 3.4% vs 0%; decreased platelet count, 10.3% vs 7.7%; febrile neutropenia, 13.8% vs 7.7%; hemorrhage, 13.8% vs 0%; neutropenia, 20.7% vs 0%; pneumonia, 17.2% vs 23.1%; sepsis, 3.4% vs 7.7%; thrombocytopenia, 27.6% vs 15.4%). Decreased hemoglobin was not reported at any time during the study.

**Discussion**

This post hoc analysis of the BRIGHT 1003 AML study extends previously reported results that show superior OS in patients with AML receiving glasdegib + LDAC versus LDAC alone, by demonstrating an improvement in survival in both patients who achieved CR and those who did not achieve CR. Furthermore, improvement was consistent across groups stratified by cytogenetic risk. The median OS among patients who achieved CR in the glasdegib + LDAC arm was > 2 years. This improvement in survival was despite the specified criteria to select patients who were ineligible for intensive chemotherapy in the study, resulting in a patient population with poor

---

**Fig. 2** ANC recovery in patients who did not achieve CR. a Percentage of patients with durable (≥ 2 consecutive visits) recovery at any time on study. b Percentage of patients with ANC recovery after the first, second, and third treatment cycle. For treatment cycle analysis, one threshold measurement was required; all patients were included regardless of their BL levels but each cycle only included remaining patients at risk in that cycle. Analysis set, N = number of patients with ANC results in the cycle; patients, n = number of patients meeting recovery criteria in the cycle. Abbreviations: ANC, absolute neutrophil count; BL, baseline; CR, complete remission; LDAC, low-dose cytarabine
prognostic features (e.g., older age). Despite the significant improvement in response rate for patients with glasdegib + LDAC, the survival benefit appears disproportionate to the rate of CR, which was < 30%. Thus, we speculated that there could have been a benefit in survival even among patients who did not achieve CR. The present analysis suggests this was indeed the case. The concept of CR being the only outcome associated with a survival benefit is applicable to intensive chemotherapy but not necessarily to other non-intensive treatment modalities. Although comparisons between trials should be considered with caution due to methodologic differences, the survival benefit of glasdegib + LDAC in patients who did not achieve CR is in line with previously reported outcomes for non-responders with other non-intensive AML therapies; median OS for non-responders (no CR or CRi) with enasidenib was 5.7 months and for non-responders (no CR or CRi) with venetoclax + LDAC, 3.5 months [8, 9]. A survival benefit in the absence of remission has been shown with agents such as azacitidine versus current commonly used treatments (median OS, 6.9 vs 4.2 months) [10].

A survival benefit in the absence of CR is accordant with the potential mechanism of action for glasdegib, which is believed to target cancer stem cells. Leukemic stem cells drive the initiation of AML and are typically resistant to conventional chemotherapy, which ultimately leads to relapse [11]. Mathematical modeling has demonstrated that stem cell proliferation and self-renewal may have a greater impact on disease progression than leukemic blasts, with high stem cell proliferation and self-renewal associated with low OS rates [12]. Preclinical studies have demonstrated that glasdegib directly inhibits leukemic stem cells and is synergistic with chemotherapeutic agents [4, 13].
An improvement in patient survival in the absence of remission has previously been reported with a number of stem cell-directed therapies (e.g., gemtuzumab ozogamicin) [11]. These studies further illustrate that response rate alone may not be an adequate marker of efficacy for stem cell-targeted therapies.

Another important finding in this analysis is the reduced risk of cytopenias in patients who did not achieve CR, with improved recovery of ANC, platelets, and hemoglobin with glasdegib + LDAC versus LDAC alone. Recovery of the three cell lineages was seen as early as cycle 1 in a meaningful proportion of patients. Additionally, more patients receiving glasdegib + LDAC were transfusion-independent. As the Hedgehog signaling pathway is not essential for normal adult hematopoiesis, this study demonstrates that treatment with glasdegib may target leukemic cells while limiting cytopenias and cytopenic complications [3, 4]. This is in contrast to many therapies for the treatment of patients with AML, which induce myelosuppression by affecting both normal and cancer cells. In addition to patients receiving glasdegib + LDAC requiring fewer transfusions, both glasdegib and LDAC can be administered at home, thereby reducing the need for hospitalization and visits to outpatient clinics in this patient population.

This study suggests that treatment with glasdegib + LDAC was associated with an acceptable safety profile in both patients who achieved CR and those who did not achieve CR. Importantly, among patients who did not achieve CR, little additional toxicity was seen with the addition of glasdegib to LDAC versus LDAC alone, and therefore, the survival and clinical benefits associated

![Fig. 4 Platelet recovery in patients who did not achieve CR.](image-url)

- **a** Percentage of patients with durable (≥ 2 consecutive visits) recovery at any time on study.
- **b** Percentage of patients with platelet recovery after the first, second, and third treatment cycles. For treatment cycle analysis, one threshold measurement was required; all patients were included regardless of their BL levels but each cycle only included remaining patients at risk in that cycle. Analysis set, N = number of patients with platelet results in the cycle; patients, n = number of patients meeting recovery criteria in the cycle. Abbreviations: BL, baseline; CR, complete remission; LDAC, low-dose cytarabine.
with glasdegib treatment occur without significant additional toxicity.

As expected in this older patient population which traditionally has median OS rates of 3–4 months, with long-term follow-up of BRIGHT 1003 AML (> 40 months), the majority of patients had discontinued treatment [14]. Overall, patients in both treatment arms predominately discontinued treatment due to insufficient response (glasdegib + LDAC, 43%; LDAC alone, 33%), with fewer patients discontinuing treatment due to AEs in the glasdegib + LDAC (17%) vs LDAC alone (28%) arm (Heuser M, et al: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial, submitted). The study protocol indicated patients should continue treatment as long as clinical benefit was observed. The best overall response with glasdegib + LDAC was frequently achieved late (after 5 cycles of therapy) into treatment (Fig S1), which lead to the recommendation that patients with AML are treated for a minimum of six cycles to allow time for a clinical response in the US Food and Drug Administration label [2]. Together, these data suggest that patients receiving glasdegib treatment should consider continuing treatment if seeing a clinical benefit, even in the absence of full hematologic remission.

The findings of this study may indicate that endpoints other than CR may be need to determine efficacy with stem cell-targeting agents, such as glasdegib, in this older patient population with AML as these may represent clinical benefit. Ongoing studies investigating the use of glasdegib in patients ineligible for intensive chemotherapy include endpoints such as overall survival, patient-reported outcomes to determine health-related quality of life, and transfusion independence [15–17].

**Conclusion**

By targeting leukemic stem cells while sparing normal hematopoiesis, glasdegib + LDAC may be an effective agent for improving survival without substantial marrow
suppression and attendant cytopenic complications. Together, these results may indicate that endpoints other than CR may be needed to determine efficacy with stem cell–targeting agents, with potential survival and clinical benefits seen in the absence of CR. Patients receiving glasdegib + LDAC seeing a clinical benefit should consider continuing treatment, even in the absence of cytologic remission. Glasdegib is being studied in a phase 3 clinical study for the treatment of AML (ClinicalTrials.gov, NCT03416179) in combination with azacitidine or 7 + 3 intensive chemotherapy [15].

### Supplementary information

**Table 6 All-causality treatment-emergent adverse events**

| N (%) | Achieved CR Glascdegib + LDAC | LDAC alone | Did not achieve CR Glascdegib + LDAC | LDAC alone |
|-------|-------------------------------|------------|-------------------------------------|------------|
| **During the first 90 days** | | | | |
| AEs | n = 15 (100) | n = 1 (100) | n = 60 (98.3) | n = 35 (100) |
| Serious AEs | 10 (66.7) | 0 | 39 (65.0) | 26 (74.3) |
| Grade 3 or 4 AEs | 14 (93.3) | 0 | 49 (81.7) | 33 (94.3) |
| Grade 5 AEs | 0 | 0 | 12 (20.0) | 13 (37.1) |
| Discontinued due to AEs | 1 (6.7) | 0 | 16 (26.7) | 12 (34.3) |
| Glasdegib dose reduced due to AEs | 2 (13.3) | N/A | 6 (100) | N/A |
| Backbone chemotherapy dose reduced due to AEs | 2 (13.3) | 0 | 3 (5.0) | 0 |
| Glasdegib temporary discontinuation due to AEs | 8 (53.3) | N/A | 30 (50.0) | N/A |
| Backbone chemotherapy temporary discontinuation due to AEs | 4 (26.7) | 0 | 16 (26.7) | 9 (25.7) |
| **After 90 days** | | | | |
| AEs | n = 14 (92.9) | n = 1 (100) | n = 29 (79.3) | n = 13 (69.2) |
| Serious AEs | 6 (42.9) | 0 | 16 (55.2) | 7 (53.8) |
| Grade 3 or 4 AEs | 10 (71.4) | 1 (100) | 20 (69.0) | 7 (53.8) |
| Grade 5 AEs | 1 (7.1) | 0 | 9 (31.0) | 3 (23.1) |
| Discontinued due to AEs | 3 (21.4) | 0 | 8 (27.6) | 5 (38.5) |
| Glasdegib dose reduced due to AEs | 4 (28.6) | N/A | 1 (3.4) | N/A |
| Backbone chemotherapy dose reduced due to AEs | 4 (28.6) | 0 | 3 (10.3) | 0 |
| Glasdegib temporary discontinuation due to AEs | 9 (64.3) | N/A | 8 (27.6) | N/A |
| Backbone chemotherapy temporary discontinuation due to AEs | 9 (64.3) | 1 (100) | 6 (20.7) | 3 (23.1) |

**AE** adverse event, **CR** complete remission, **LDAC** low-dose cytarabine, **N/A** not applicable

**Additional file 1: Fig. S1.** Duration of treatment with best overall response. **a** For patients receiving glasdegib + LDAC. **b** For patients receiving LDAC alone. Abbreviations: CR, complete remission; CRi, CR with incomplete hematologic response; EOT, end of treatment; LDAC, low-dose cytarabine; MR, minor response; PR, partial response; SD, stable disease

**Additional file 2: Fig. S2.** Kaplan–Meier plots of OS with censoring for systemic follow-up therapies. **a** In patients who achieved CR. **b** In patients who did not achieve CR. Abbreviations: CI, confidence interval; CR, complete remission; LDAC, low-dose cytarabine; N/E, not evaluable; OS, overall survival

**Additional file 3: Fig. S3.** Kaplan–Meier plots of OS with censoring for systemic follow-up therapies. **a** In patients who achieved CR. **b** In patients who did not achieve CR. Abbreviations: CI, confidence interval; CR, complete remission; LDAC, low-dose cytarabine; N/E, not evaluable; OS, overall survival

**Additional file 4: Fig S4.** Blood count recovery in patients who did not achieve CR. Percentage of patients with a. **ANC** absolute neutrophil count; **b** hemoglobin; **c** platelets recovery during cycles one to ten. One threshold measurement was required; all patients were included regardless of their BL levels but each cycle only included remaining patients at risk in that cycle. Analysis set, N = number of patients with ANC results in the cycle; patients, n = number of patients meeting recovery criteria in the cycle. Abbreviations: ANC, absolute neutrophil count; BL, baseline; CR, complete remission; LDAC, low-dose cytarabine

**Additional file 5: Table S1.** Patient disposition

**Additional file 6: Table S2.** Treatment-emergent all-causality adverse events* occurring during first 90 days and after 90 days of therapy

**Abbreviations**

**AE**: Adverse event; **AML**: Acute myeloid leukemia; **ANC**: Absolute neutrophil count; **BL**: Baseline; **CI**: Confidence interval; **CR**: Complete remission; **CRi**: Complete remission with incomplete hematologic recovery; **ECOG PS**: Eastern Cooperative Oncology Group performance status; **ELN**: European LeukemiaNet; **EOT**: End of treatment; **HR**: Hazard ratio; **LDAC**: Low-dose cytarabine; **LSC**: Leukemic stem cell; **MLFS**: Morphologic leukemia-free state; **MR**: Minor response; **N/A**: Not applicable; **N/E**: Not evaluable; **OS**: Overall survival; **PR**: Partial remission; **PRBC**: Packed red blood cells; **PRI**: Partial remission with incomplete hematologic recovery; **SD**: Stable disease; **SMO**: Smoothened; **TEAE**: Treatment-emergent adverse event
Acknowledgements
This study was sponsored by Pfizer. Medical writing support was provided by Gemma Shay, PhD, at Engage Scientific Solutions, and was funded by Pfizer.

Authors’ contributions
Conception or design of the study: JEC, RF, WWM, TOB, AOC, and GC. Acquisition of data: JEC, FH, WF, BDS, TR, PMs, AC, BL, MAS, DAP, and MH. All authors contributed equally to the analysis and interpretation of data. All authors contributed equally to the preparation and final approval of the manuscript.

Funding
This study was sponsored by Pfizer.

Availability of data and materials
Upon request, and subject to certain conditions, criteria, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data may be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent before study procedures began. The protocol was approved by institutional review boards at each study site.

Consent for publication
Not applicable.

Competing interests
JEC received research funding and consulting honoraria from Pfizer, Novartis, Astellas, Daiichi Sankyo, and Celgene. FH received honoraria from Pfizer. WF has participated in advisory boards for Amgen, Pfizer, Novartis, Jazz Pharmaceuticals, and ARIAD/Incyte; received research funding from Amgen; received support for meeting attendance from Amgen, Jazz Pharmaceuticals, Daiichi Sankyo Oncology, and Servier; and received support for medical writing from Amgen, Pfizer, and AbbVie. BDS served on an advisory board and was a consultant for Celgene, Jazz Pharmaceuticals, Novartis, and Pfizer. TR received research funding from Pfizer. PM serves on an advisory board for Celgene, Jazz Pharmaceuticals, Janssen, and Novartis and has received funding from Pfizer and Celgene. AC received honoraria from Novartis, Janssen, Pfizer, Gilead Sciences, Celgene, Incyte, and Merck. BL served on an advisory board and received honoraria from Pfizer. MG is an advisory board member for Celgene. DAP has served as an advisory board member for Pfizer, Servier, Takeda, Cusis, Celgene, Agios, AbbVie, and Celvad and has received research funding from Pfizer and Agios. RF, WWM, TOB, AOC, and GC are employees and shareholders of Pfizer. MH received research funding and honoraria from Pfizer.

Author details
1Georgia Cancer Center, Augusta, CA, USA. 2Otto-von-Guericke University Medical Center Magdeburg, Magdeburg, Germany. 3Internal Medicine II, University Hospital Jena, Jena, Germany. 4Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 5Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. 6Department of Hematology, Medical University of Łódź and Copernicus Memorial Hospital, Łódź, Poland. 7Hospital Universitario iPolitecnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain. 8Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. 9Juruwinski Hospital at Hamilton Health Sciences, Hamilton, ON, Canada. 10Leukemia Program, Cleveland Clinic, Cleveland, OH, USA. 11Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA. 12Pfizer Oncology, New York, NY, USA. 13Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Received: 30 April 2020 Accepted: 29 June 2020
Published online: 14 July 2020

References
1. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:78–9.
2. Pfizer Inc. DAURISMO® (glasdegib) prescribing information, http://labeling, pfizer.com/ShowLabeling.aspx?id=11336. Accessed 28 Aug 2019.
3. Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonomici S, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell. 2009;4:558–8.
4. Fukushima N, Minami Y, Kakuuchi S, Kuvatsuka Y, Hayakawa F, Jamieson C, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci. 2016;107:1422–9.
5. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson M, Blum J, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia. Nature. 2009;458:776–8.
6. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell. 2009;4:559–67.
7. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–9.
8. Polleyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, et al. Enasidinib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33:2575–84.
9. Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase IIb/II study. J Clin Oncol. 2019;37:1277–84.
10. Dombret H, Seymour JF, Butyn M, Wierzbowiska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–9.
11. Polleyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129:1627–35.
12. Steinh T, Baran N, Ho AD, Marciniak-Czochra A. Cell division patterns in acute myeloid leukemia stem-like cells determine clinical course: a model to predict patient survival. Cancer Res. 2015;75:940–9.
13. Sadaranangi A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 2015;13:98.
14. Lancet JE. Is the overall survival for older adults with AML finally improving? Best Pract Res Clin Haematol. 2018;31:387–90.
15. Cortes JE, Dombret H, Merchant A, Tauchi T, DiRenzo CG, Sleight B, et al. Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. Future Oncol. 2019;15:3511–45.
16. Zeidan AM, Schuster MW, Krauter J, Maertens JA, Gyan E, Joris M, et al. The clinical benefit of glasdegib in combination with azacitidine or low-dose cytarabine in patients with acute myeloid leukemia. Blood. 2019;134:3916.
17. Wang ES, Bell T, Zeidan AM, Bhattacharyya H, Kudla A, Chan G, et al. Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA). J Clin Oncol. 2020;38:abstr 7527.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.